CurrentCignaPolicy IP0680

Litfulo Prior Authorization Policy

Sets Cigna prior authorization criteria for coverage of Litfulo (ritlecitinib capsules) for treatment of alopecia areata in patients aged ≥12 years, defines initial and continuation approval criteria, duration of approvals, and lists disallowed concurrent uses. Includes appendix of biologic and oral agents for reference.

Policy Summary

PayerCigna

PolicyLitfulo Prior Authorization Policy

Policy CodePolicy IP0680

Change TypeNew policy; annual revision (no criteria changes)

Effective DateSep 1, 2025

Next Review Date

Key ActionSubmit prior authorization requests; initial approvals require prescription by or consultation with a dermatologist and are granted for 6 months (continuation approvals require documentation of clinical benefit and are granted for 1 year).

SourceLink

POLICY UPDATE CHANGES

New policy created with initial effective/revision date 11/01/2024 and annual revision noted 09/01/2025 stating no criteria changes.

2Approval pathways (Initial; Continuation)

6 monthsInitial approval duration

1 yearContinuation approval duration

≥50%Scalp hair loss threshold

Coverage Summary

coverage_stance: covered_with_criteria; indication: FDA‑approved for severe alopecia areata in patients ≥12 years. Scope: Sets Cigna prior authorization criteria for coverage of Litfulo (ritlecitinib) for alopecia areata in patients aged ≥12 years, defining initial and continuation approval criteria, approval durations, and disallowed concurrent uses. Approval durations: 6 months initial (Initial Therapy) and 1 year continuation (Patients currently receiving Litfulo). Disallowed concurrent uses include combination with biologics, topical JAK inhibitors, biologic immunomodulators, or other potent immunosuppressants (Conditions Not Covered).

FDA-Approved Indication - Alopecia Areata

Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy

Patient is ≥ 12 years of age
Patient has a current episode of alopecia areata lasting for ≥ 6 months
Patient has ≥ 50% scalp hair loss
iv. Patient has tried at least ONE of the following
- Conventional systemic therapy (examples include corticosteroids, methotrexate, and cyclosporine). Note: An exception to the requirement for a trial of one conventional systemic agent can be made if the patient has already tried Leqselvi (deuruxolitinib tablets) or Olumiant (baricitinib tablets).
- High- or super-high potency topical corticosteroid
The medication is prescribed by or in consultation with a dermatologist

B) Patient is Currently Receiving Litfulo

Patient is ≥ 12 years of age
Patient has been established on Litfulo for at least 6 months
Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Litfulo) in extent and density of scalp hair loss
According to the prescriber, the patient continues to require systemic therapy for treatment of alopecia areata

Conditions Not Covered / Exclusions

Conditions Not Covered (Not Medically Necessary)

Litfulo for any other use is considered not medically necessary, including but not limited to:

ALL of the following

Concurrent use with a biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition (combination therapy generally not recommended due to higher rate of adverse events and lack of controlled data supporting additive efficacy)
Concurrent use with a topical Janus Kinase inhibitor (JAKi)
Concurrent use with a biologic immunomodulator (examples: Adbry, Cinqair, Dupixent, Fasenra, Nucala, Tezspire, Xolair)
Concurrent use with other potent immunosuppressants (e.g., cyclosporine, azathioprine)

Provider Actions

Prior Authorization

Prior authorization required

Prior Authorization is recommended for benefit coverage of Litfulo; approvals are provided for the durations specified. Initial approvals are for 6 months and continuation approvals are for 1 year. Initial approval requires the medication be prescribed by or in consultation with a dermatologist.

Initial approval duration: 6 months
Continuation approval duration: 1 year
Initial prescription by or in consultation with a dermatologist

Documentation Required

Clinical response documentation for continuation

For continuation (patients currently receiving Litfulo), the prescriber must document a beneficial clinical response and that the patient continues to require systemic therapy.

Beneficial clinical response defined as improvement from baseline in extent and density of scalp hair loss

Denial Risk

Not medically necessary for concurrent therapies

Claims for Litfulo used in combination with certain other therapies are considered not medically necessary and will not be covered.

Concurrent use with biologics or targeted synthetic oral small molecule drugs
Concurrent use with topical JAK inhibitors
Concurrent use with biologic immunomodulators (examples: Adbry, Cinqair, Dupixent, Fasenra, Nucala, Tezspire, Xolair)
Concurrent use with other potent immunosuppressants (e.g., cyclosporine, azathioprine)

Background

Mechanism: JAK/TEC pathway inhibitor (ritlecitinib inhibits JAK3 and TEC pathways) indicated for severe alopecia areata in patients ≥12 years.

Role: JAK inhibitors are identified among systemic, steroid‑sparing treatment options for extensive hair loss and are considered the ideal option among systemic, steroid‑sparing agents.

Typical first‑line adult treatments: high‑ or super‑high potency topical corticosteroids and/or systemic corticosteroids.

Clinical Thresholds / Definitions

Age≥ 12 years

Current episode duration≥ 6 months

Scalp hair loss≥ 50% scalp hair loss

Established on therapy (continuation)at least 6 months

Definitions

Initial Therapy: Patient initiating Litfulo or with <6 months of prior Litfulo therapy; approvals are granted for 6 months if all initial criteria are met (age ≥12, current episode ≥6 months, ≥50% scalp hair loss, prior trial of specified therapies, and prescribed by or in consultation with a dermatologist).

Currently Receiving Litfulo: Patient established on Litfulo for at least 6 months; continuation approvals are granted for 1 year if response is documented (beneficial clinical response from baseline in extent and density of scalp hair and continued need for systemic therapy).